Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957318 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL7606639 | 0.81 | KIF11 (0.46) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL15355750 | 0.80 | CNR2 (0.46) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL1637413 | 0.79 | ESR1 (0.56) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL22150730 | 0.77 | KIF11 (0.71) | LMNAKIF11KCNH2SMN1; SMN2 | |
| SCHEMBL17472445 | 0.77 | NPC1 (0.43) | ALDH1A1LMNAMAPTCA1CA2 | |
| SCHEMBL2439740 | 0.77 | CA1 (0.44) | ALDH1A1LMNAALOX15APEX1MAPK1 | |
| SCHEMBL7736545 | 0.76 | CYP2C19 (0.41) | ALDH1A1LMNAALOX15MAPK1KIF11 | |
| SCHEMBL21254283 | 0.76 | ESR2 (0.54) | ALDH1A1KIF11KCNH2MAPTRAB9A | |
| SCHEMBL7708779 | 0.76 | KIF11 (0.69) | LMNAKIF11KCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394356-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8017105-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7297456-B2 | Photoconductors containing crosslinked polycarbonate polymers | XEROX CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-7229606-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229732-B2 | Imaging members with crosslinked polycarbonate in charge transport layer | XEROX CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070020185-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070020184-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070003479-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC., A DELAWARE CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1716871-A2 | Diagnostic imaging contrast agents with extended blood retention | EPIX Pharmaceuticals, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7060250-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-7011815-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040202613-A1 | Chelate compounds | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-6676929-B2 | MEDICAL DIAGNOSIS; GADOFOSVESET | EPIX MEDICAL, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030180223-A1 | Magnetic resonance imaging | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003029257-A1 | (ETHYLENE)-(PROPENE/BUTENE)-PHOSPHODIESTER TRIAMINE PENTAACETIC ACID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | WO | disclosed |
| US-20020164289-A1 | Medical diagnosis | CITIZENS BANK, N.A. | 2002-11-07 | — | — | US | disclosed |
| EP-0806968-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | Epix Medical, Inc. (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023526-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | EPIX MEDICAL, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164289-A1 | Medical diagnosis | FABP1, B2M, MB | ALDH1A1 2948/4885LMNA 2326/4885ALOX15 3443/4885 |
| US-20070003479-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | ALDH1A1 2702/4885LMNA 2199/4885ALOX15 3566/4885 |
| US-20030180223-A1 | Magnetic resonance imaging | BHMT, FABP1, FABP7 | ALDH1A1 3269/4885LMNA 2703/4885ALOX15 3748/4885 |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | FABP1, BHMT, FABP3 | ALDH1A1 2826/4885LMNA 1618/4885ALOX15 3729/4885 |
| US-20070020185-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | ALDH1A1 2702/4885LMNA 2199/4885ALOX15 3566/4885 |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | FABP1, B2M, BHMT | ALDH1A1 2702/4885LMNA 2199/4885ALOX15 3566/4885 |
| US-20040202613-A1 | Chelate compounds | FABP1, BHMT, FABP3 | ALDH1A1 3477/4885LMNA 3566/4885ALOX15 3881/4885 |
| US-20070020184-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | ALDH1A1 2702/4885LMNA 2199/4885ALOX15 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.